학술논문
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial
Document Type
Article
Author
Source
In The Lancet Oncology February 2022 23(2):220-233
Subject
Language
ISSN
1470-2045